VCEL Vericel Corporation

Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced presentations at multiple upcoming investor conferences.

Nick Colangelo, president and CEO will present the latest company overview at:

• The Cowen 39th Annual Health Care Conference in Boston, MA on Monday, March 11, 2019 at 2:10PM ET with live webcast at http://wsw.com/webcast/cowen52/vcel/ 
• The Canaccord Genuity Musculoskeletal Conference in Las Vegas, NV on Tuesday, March 12, 2019 at 9:30AM PT with live webcast at http://wsw.com/webcast/canaccord33/vcel/

The presentations may also be accessed from the news and events section of the Vericel website.

About Vericel CorporationVericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets.  The company markets two cell therapy products in the United States.  MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults.  Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area.  For more information, please visit the company's website at www.vcel.com.

Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2019 Vericel Corporation. All rights reserved.

Global Media Contacts:David SchullRusso Partners LLCDavid.schull@russopartnersllc.com+1 212-845-4271 (office)+1 858-717-2310 (mobile)

Karen ChaseRusso Partners LLCKaren.chase@russopartnersllc.com+1 646-942-5627 (office)+1 917-547-0434 (mobile)

Investor Contacts:Chad RubinSolebury Troutcrubin@troutgroup.com+1 (646) 378-2947

Lee SternSolebury Troutlstern@troutgroup.com+1 (646) 378-2922